# Transcutaneous afferent patterned stimulation reduces essential tremor symptoms through modulation of neural activity in the ventral intermediate nucleus of the thalamus

**Luu, Cuong P.<sup>1,2</sup>**, Ranum, Jordan<sup>2</sup>, Youn, Youngwon<sup>1,2</sup>, Perrault, Jennifer L.<sup>2</sup>, Krause, Bryan<sup>3</sup>, Banks, Matthew<sup>3</sup>, Buyan-Dent, Laura<sup>4</sup>, Ludwig, Kip A. <sup>1,2</sup>, Lake, Wendell B. <sup>1,2</sup>, & Suminski, Aaron J.<sup>1,2</sup>

<sup>1</sup>Department of Neurological Surgery, University of Wisconsin-Madison <sup>2</sup>Wisconsin Institute for Translational Neuroengineering, University of Wisconsin-Madison <sup>3</sup>Department of Neuroscience, University of Wisconsin-Madison <sup>4</sup>Department of Neurology, University of Wisconsin-Madison

Address for Correspondence: Aaron J. Suminski 1111 Highland Ave, Rm. 3555 Madison, WI 53705

Keywords: Essential Tremor, Human, Peripheral Nerve Stimulation, Neuromodulation, VIM, cerebello-thalamo-cortical network, Deep Brain Stimulation

Words in Abstract: 217 Total Words: 2902 (Introduction, Results, Discussion, Conclusion) Number of Figures: 4 main figures + 8 supplementary figures Number of Tables: 1

#### Abstract

Essential tremor (ET), the most common movement disorder in adults, presents with involuntary shaking of the arms during postural hold and kinetic tasks linked to dysfunction in the cerebellothalamo-cortical (CTC) network. Recently, transcutaneous afferent patterned stimulation (TAPS), applied through a wrist-worn device, has emerged as a non-invasive therapy for medication refractory ET. However, its mechanism remains unclear. We hypothesize that TAPS reduces tremor through modulation of the VIM thalamus in the CTC network. Employing refractory ET patients seeking VIM deep brain stimulation (DBS), we quantified clinical tremor improvement following TAPS treatment in a pre-operative setting, followed by intra-operative, microelectrode recording of the contralateral thalamus with concurrent TAPS treatment on and off. After one preoperative session, TAPS significantly reduces upper limb tremor, with asymmetric effect favoring the treated limb and greatest improvement tending to kinetic tremor. The magnitude of TAPS-related tremor reduction demonstrates a positive correlation with the modulation of alpha and beta band LFPs in the VIM. TAPS also modulated spiking activity in the VIM, though it was uncorrelated with the degree of tremor reduction. Of note, TAPS related modulation of LFPs and spiking activity was greatest near the optimal placement location for DBS lead in treating ET. In sum, TAPS likely reduces tremor in ET by modulating the VIM and connected nodes in the cerebello-thalamo-cortical pathway.

#### 1 Manuscript

2

#### 3 Introduction

4 Essential tremor (ET) is the most common movement disorder in adults, and its impact is rising 5 as a greater share of the world population age.<sup>1,2</sup> ET patients experience debilitating symptoms 6 from involuntary, rhythmic action tremor of the arms, though shaking can also involve the head, 7 voice, and legs.<sup>3,4</sup> These action tremors often involve two clinically distinct types with intrinsically different frequency: kinetic tremors, typically under 6 Hz, and postural tremors, which range 8 9 from 6 to 12 Hz.<sup>3,5–9</sup> Their exact etiology remains unclear, but, complementary evidence from postmortem histology<sup>10,11</sup>, imaging<sup>12</sup>, and electrophysiological<sup>13</sup> studies point to dysfunction in 10 the cerebello-thalamo-cortical (CTC) network—a network that links the deep cerebellar nuclei to 11 12 the motor cortex via the motor and sensory thalamus, including the ventral intermediate (VIM) 13 nucleus. The disruption of this network hinders one's ability to evaluate and refine goal directed movement.14-20 14 15

16 There remains a significant gap in the treatment of ET. Frontline medical intervention with

- primidone and propranolol may improve tremor to a modest extent, but about 50% of patients
   stop medications due to side effects.<sup>21,22</sup> Surgery for deep brain stimulation (DBS) targeting the
- 19 VIM demonstrates a 60-75% reduction in tremor, yet up to 86% suffer ataxia, dysarthria, or
- 20 dysgeusia and 15-73% eventually lose tremor control.<sup>23,24</sup> The concerns of side effects, therapy
- habituation, and cost from DBS deter approximately half of eligible candidates.<sup>25</sup> Thus, VIM
- 22 DBS is generally reserved for patients with severe, debilitating ET. Recently, a less invasive
- 23 alternative, magnetic resonance-guided focused ultrasound (MRgFUS), has shown promise in
- treating moderate to severe, refractory ET by creating a lesion in the VIM.<sup>26–29</sup> Despite its safety
- and efficacy, MRgFUS adoption has also remain limited due to its need for specialized
- equipment, irreversible nature, and high relapse rate.<sup>30</sup> Taken together, the limitations of current
- therapies leave many ET patients, especially those with mild to moderate symptoms, without
- 28 effective treatment options.
- 29
- 30 In response to these limitations, transcutaneous afferent patterned stimulation (TAPS<sup>™</sup>)
- 31 emerged as a non-invasive, on-demand therapy to reduce hand tremor in ET patients.<sup>31</sup> TAPS
- 32 applies electrical bursts that alternate between the median and radial nerves on the wrist,
- 33 leveraging afferent projections from these nerves to stimulate the VIM. Importantly, electrical
- 34 stimulation of the median nerve is known to directly modulate neural activity throughout the
- 35 somatosensory thalamus, including the VIM.<sup>32–34</sup> The alternating burst of TAPS, whose
- 36 frequency is tuned to the tremor frequency of each patient, is intended to disrupt synchronized, 37 pathological firing of VIM neurons through a process known as coordinated reset.<sup>35</sup> TAPS has
- 38 gained FDA approval for ET treatment, demonstrating efficacy in a randomized controlled trial
- 39 and a 38-83% tremor reduction lasting about one hour after each session.<sup>36,37</sup> Its tremor-
- 40 reducing effects have been shown to accumulate over months of treatment, with no habituation
- 41 and minimal side effects.<sup>38</sup>
- 42
- 43 As proposed in theory, TAPS achieves tremor reduction by desynchronizing pathological,
- 44 oscillatory neural activity in the CTC network.<sup>39</sup> However, outside of data showing clinical
- 45 improvement and a small FDG-PET/ CT study, there is limited evidence elucidating the
- underlying mechanism of TAPS and its potential impact on the brain.<sup>40,41</sup> Here, we examined
- 47 what effect TAPS has on the clinical components of ET and how it may modulate the CTC
- 48 network. We hypothesized that TAPS would modulate the VIM thalamus in patients who see
- 49 tremor reduction benefits. Our results provide strong evidence suggesting that tremor
- 50 improvement resulting from TAPS therapy is related to modulation of neural activity in the CTC
- 51 network, in particular, modulation of alpha band local field potentials (LFP).

### 52

#### 53 Results

54

#### 55 Study demographics, design, and TAPS

56

57 To prospectively study the effect of TAPS across tremor types and on thalamus activity, we 58 enrolled 9 adults (2 female, Mean age ± SD: 65 ± 7 years) with medication refractory ET 59 seeking DBS placement in the VIM. Demographic, medical history, and study-related measures are reported in Table 1. Using the Essential Tremor Rating Assessment Scale (TETRAS), all 60 subjects presented with moderate hand tremor scores (Mean  $\pm$  SD of spiral drawing score: 2.8  $\pm$ 61 62 0.8; upper limb tremor:  $2.3 \pm 0.5$ ) approximating an average tremor amplitude of 5 cm. When 63 surveyed with the Quality of Life in Essential (QUEST) questionnaire, tremor was present during 64 most of patients' waking hours (Mean ± SD: 82.1 ± 15.4%), with the greatest impact on hobbies/ 65 leisure activities (Mean  $\pm$  SD: 85.2  $\pm$  15.5%) and general physical activities (Mean  $\pm$  SD: 66.1  $\pm$ 66 25.2%).

67

68 Patients underwent the study in 2 phases, in which they donned a wrist-worn stimulator and

69 received standard TAPS treatment on their dominant limb (Fig. 1A, B; see Methods 1.2). TAPS 70 treatment was personalized for each participant at their tremor frequency (Mean ± SD: 5.4 ± 1.3)

71 Hz) and at the maximum tolerable stimulation amplitude (Mean ± SD: 7.0 ± 1.1 mA), calibrated

according to the manufacturer's instructions. These stimulation parameters were held constant
 between both the pre-operative and intra-operative phases. Phase 1, pre-operative, further

involved the assessment of tremor severity using the TETRAS before and after TAPS treatment
 (Fig. 1C). Phase 2, intra-operative, occurred during the stereotactic operation to place DBS

(Fig. 1C). Phase 2, intra-operative, occurred during the stereotactic operation to place DBS
 electrode in the VIM, a standard surgery to treat refractory ET (Fig. 1D). Of note, we removed

- 77 subject 8 from subsequent analysis because the individual reported an atypical, long-term
- tremor suppression for one month after their TAPS treatment in phase 1.

#### 79

# 80 Individual and aggregated upper limb tremor tasks significantly improved in the 81 dominant limb following TAPS treatment

82

83 Our first goal was to guantify the therapeutic effect of TAPS. We scored tremor severity using 84 the 5 upper limb tasks in TETRAS before and after TAPS treatment, calculating tremor 85 improvement as the difference in pre- and post-treatment scores (see Methods 1.3). Consistent with previous randomized controlled trials<sup>36</sup>, TAPS significantly improved the average total 86 87 upper limb TETRAS score for the treated limb (0.61, p=0.008). Interestingly, we also found that 88 TAPS resulted in a significant improvement in the average total upper limb TETRAS score of 89 the untreated limb (0.35, p=0.008); however, improvement in the treated, dominant limb, was 90 significantly greater than the untreated limb (p=0.047) (Fig. 2A). Given that ET is known to 91 manifest with distinct postural and kinetic tremor components, we were also interested in 92 examining TAPS related improvements in the individual upper limb tremor tasks. The treated 93 hand showed a significant improvement in the forward postural hold (0.625, p=0.016), spiral 94 drawing (0.875, p=0.039), and dot approximation (0.563, p=0.031) tasks with trends toward 95 significant effects in the lateral postural (p=0.063) and kinetic (p=0.063) tremor measures 96 (Supplementary Fig. S1). In contrast, the untreated limb showed no significant improvement in 97 any of the individual tasks (p>0.05). We further analyzed handwriting, though separately as we 98 did not collect handwriting data from the untreated, non-dominant limb, and found a significant 99 improvement in handwriting tremor score resulting from TAPS (0.79, p=0.002) (Supplementary 100 Fig. S2).

101

### 102 **TAPS therapy enhanced improvement of kinetic tremor in the dominant limb**

#### 103

104 Given the significant reduction in tremor severity observed for both limbs, we were interested in 105 isolating the effect of TAPS to the treated limb. We captured this through the fractional tremor 106 reduction (fTR) score, calculated as a difference in average upper limb tremor improvement 107 between the treated and untreated limb with normalization to the untreated limb value (Eq. 1). 108 fTR ranged from -0.67 to 5.00, showing that subjects' responses to TAPS had a wide dynamic 109 range corresponding to observed qualitative tremor improvement (Fig. 2B, C). Here, half of the 110 subjects exhibited fTR≥1 (i.e. double the tremor improvement in the treated limb compared to 111 the untreated limb).

112

113 To continue the examination of how TAPS may impact the two components of ET, we explored 114 the differential impact of TAPS on tasks that were grouped into either the kinetic or postural 115 tremor components. We questioned if initial tremor severity correlated with fTR as tremor severity may be predictive of ET onset and progressive atrophy along neural pathways.<sup>42,43</sup> We 116

- 117 used the pre-treatment TETRAS scores as a proxy for initial tremor severity. Regression
- 118 analysis found no relationship between fTR scores and tremor severity for postural or kinetic
- 119 tremor (Fig S3). Next, we explored if TAPS exhibited differential improvement in either kinetic
- 120 tremor or postural tremor. We discovered that improvement in kinetic tremor scores of the 121
- treated limb displayed a significant positive relationship with fTR, explaining 94.3% of the 122 variability (F(3,4)=39.623, p=0.002) (Fig. 2D). In contrast, there was no relationship between
- 123 improvement in postural tremor and fTR (p=0.967) (Fig. 2E).
- 124

#### 125 Fractional tremor reduction in the dominant limb directly correlates with LFP modulation 126 in the VIM

127

128 Next, to understand TAPS's therapeutic mechanism, we investigated if therapeutic effect was 129 mediated by changes in neural activity within a prominent node in the CTC network, the VIM. 130 During each patient's awake DBS implant surgery, we advanced 3 microelectrodes along a 131 trajectory targeting the VIM, recording at selected depths in and around the VIM while TAPS 132 treatment was ON and OFF. Subsequently, we processed the recordings for the power of the 133 LFP at different frequency bands from 0 to 200 Hz, and quantified the modulation index of LFP 134 (MI<sub>LFP</sub>) as the fractional difference in power between the ON and OFF states (Fig. 3A, B). Since 135 we suspected that TAPS may act on the same neural substrate as DBS, we performed an initial 136 survey of the relationship between MILFP and distance from the final implant location of the DBS 137 lead (i.e. the distal edge of the most distal contact on the DBS lead; see Methods 1.4). 138 Regression analysis, however, found no relationship between MILFP in any frequency band and 139 distance from the DBS lead implant location (Supplementary Fig. S4). We examined this 140 relationship more deeply by parsing MER recordings that were putatively made within the VIM 141 (Fig. 3C, ≤ 5mm from implant location) or outside of it (>5mm). Here, regression analysis found 142 that, only within the VIM, the alpha band MI<sub>LFP</sub> was strongly modulated closer to the DBS 143 implant location (R2=0.1221, F(1,52)=8.371, p=0.006) (Fig. 3D, F). In contrast, no relationship 144 between MI<sub>LFP</sub> and distance to implant location was found outside of the VIM in any frequency 145 band (Fig. 3 E, F; Supplementary Fig. S5), suggesting that TAPS and DBS may share a 146 common mechanism for mitigating tremor. 147

148 Since tremor improvement due to TAPS, measured by fTR, varied widely among patients, we

- 149 examined if there was a relationship between fTR and changes in neural activity quantified by
- 150 MI<sub>LFP</sub> across different frequency bands. Within the VIM, regression analysis found that patients
- 151 who experienced the largest fTR due to TAPS had significantly increased MI<sub>LFP</sub> in only the
- 152 alpha (F(1,52) =15.313, p<0.001) and beta bands (R2=0.255, F(1,52)=19.16, p<0.001) (Fig. 3G, 153 I). For recording locations outside the VIM, there was no relationship between tremor reduction

and MI<sub>LFP</sub> for any band (Fig. 3H, I; Supplementary Fig. S6). Notably, this effect was specific to
 tremor reduction as measured by fTR; a separate regression analysis showed no relationship
 between MI<sub>LFP</sub> within the VIM and total tremor improvement in the treated upper limb (i.e. no
 normalization by effect in the untreated limb).

- 158
   159 TAPS suppresses multiunit spiking in the VIM, though effect was homogenous among
   160 patients
- 161

162 In addition to thalamic LFP, we also examined the modulation of multiunit spiking activity in

163 response to TAPS treatment. One representative sample, recorded within the VIM 0.5 mm from

the final implant location, showed a pronounced reduction in spike rate during TAPS treatment

(Fig. 4A, B). We limited our analysis to recording depths within the VIM (i.e. ≤5 mm from thefinal implant location) where the minimum firing rates was at least 1 Hz while TAPS was OFF.

167 We used a resampling procedure to estimate the most likely multiunit firing rate. This was

168 necessary because many time series had different durations due to removal of motion artifacts

- 169 (Fig. 4C, D). In the 37 recordings that met this criterion, we characterized the modulation index
- 170 of spikes (MI<sub>Spikes</sub>) as the fractional difference in spike counts between the ON and OFF states
- 171 of TAPS. MI<sub>Spikes</sub> significantly decreased closer to the final implant location, with trend toward
- 172 MI<sub>Spikes</sub>= -1 indicating that TAPS suppressed spiking activity to near 0 (R2=0.104,
- 173 F(1,35)=5.197, p=0.029) (Fig. 4E). No significant relationship was observed between MI<sub>Spikes</sub>
- and isolated tremor improvement (p=0.777) (Fig. 4F). At distances >5mm, MI<sub>Spikes</sub> ranged from -
- 175 1 to 0.5, but it did not exhibit a significant relationship with either distance from implant location
- or isolated tremor improvement (p=0.768 and p=0.949, respectively).

### 178 Discussion

179

180 In the effort to find non-invasive therapy for ET, transcutaneous afferent patterned stimulation of 181 the median and radial nerves near the wrist (i.e. TAPS) has been shown to reduce limb tremors,

but its mechanism of action remains unclear. Putatively, stimulation alternating between the

- 183 median and radial nerves serves to provide a desynchronizing input to the sensorimotor
- 184 thalamus (i.e. VIM) via projections ascending in the dorsal column and/or spinothalamic
- pathways. The VIM links cerebellar output with the sensorimotor cortex and serves as a major
- node in the CTC network, the hypothesized locus of dysfunction in ET<sup>10–13</sup>. Given this
- 187 anatomical substrate and that lesional therapies<sup>26-29</sup> and DBS<sup>23,24</sup> target the VIM for treatment of
- 188 ET, we hypothesized that VIM is a likely site of the therapeutic effect of TAPS. Here, we
- demonstrated that TAPS of the median and radial nerves directly modulate the activity of both
- 190 local field potentials and spiking activity in the VIM thalamus. Specifically, our data
- demonstrates that patients who have the greatest modulation of alpha and beta LFP caused by
- 192 TAPS experienced the largest reduction in tremor symptoms. Additionally, sites exhibiting the
- 193 largest modulation of both LFP and spiking activity are generally located closest to the
- 194 placement of the DBS lead for treatment of ET (annotated as the distance from implant location
- and marked by the distal edge of the distal electrode on the DBS lead). Finally, our data further suggested that TAPS have an asymmetric effect on tremor reduction in different subtypes, with
- an enhanced effect on kinetic tremor relative to postural tremor in the treated limb.
- 198

#### 199TAPS acts on the cerebello-thalamo-cortical network

200

201 There is strong evidence linking dysfunction throughout the CTC network, particularly

- thalamocortical circuits, to ET.<sup>13,44–48</sup> For example, Kane et al. reported increased theta (4-8Hz)
- and alpha (8-12Hz) LFP power in thalamic nuclei receiving cerebellar input (i.e. VIM) compared
- to nuclei receiving input from the basal ganglia or somatosensory afferents. In conjunction,

205 LFPs recorded from the VIM demonstrated increased synchrony in ET patients compared to individuals diagnosed with other neurodegenerative diseases<sup>46</sup>, and motor cortex alpha LFP 206 power is altered in ET patients when compared to healthy controls.<sup>13</sup> Moreover, electrical 207 208 stimulation of the median nerve is known to modulate neural activity throughout the CTC network with the most direct effects being found in the somatosensory thalamus.<sup>32–34</sup> Our data 209 210 bridge the evidence describing CTC network dysfunction in ET and a putative therapeutic 211 mechanism for TAPS, that is the modulation of neural activity in VIM. Notably, we show that 212 TAPS of the median and radial nerves increased modulation of VIM alpha and beta bands LFP 213 in subjects with higher fTR (Fig 3G, I), indicating a mechanistic role for VIM in reducing tremor. 214 This effect was limited to the VIM as no LFP modulation was observed at distances >5mm from 215 the location of the implanted DBS lead (Fig 3E, H). Notably, modulation of multiunit spiking 216 activity was also only observed within the VIM; but, unlike alpha and beta LFP, had no 217 relationship to reduction of tremor symptoms (Fig 4E, F). The dissociation between LFP and 218 spiking activity modulation's relationship to tremor reduction (i.e. fTR) is particularly interesting and potentially meaningful given their distinct roles.<sup>49</sup> Specifically, Low-frequency field potentials 219 220 typically reflect summed synaptic currents—potentially representing inputs to an area—while 221 single/ multiunit activity likely represents outputs. In this light, the mechanism of TAPS may be 222 thought to act on the CTC network more broadly via the VIM, and not on local neural 223 populations in the VIM alone.

224

225 In validating our neural data, we believe that these results are not confounded by artifacts from 226 TAPS applied at the wrist. First, raw time series showed no evidence of stimulation artifacts (Fig 227 4A, B; Supplementary Fig. S8). Second, modulation of neural activity related to tremor reduction 228 (i.e. fTR) was only found in a spatially defined region, putatively within the VIM. Given the small 229 range between the most dorsal and ventral recording locations (~10mm), we would expect any 230 presenting stimulation artifact to appear at all depths-that was not seen. Finally, the wrist 231 stimulation device is wireless and battery-powered with a localized, bipolar electrode geometry, 232 mitigating the effect of ground loop contamination and broad spread of the applied electric field.

233

#### 234 Heterogeneous tremor improvement in response to TAPS treatment

235 236 In our study, we observed that TAPS significantly improved tremor in both the treated and 237 untreated limb. As described above, the effect of TAPS is putatively due to modulation of the 238 CTC network via the VIM contralateral to the treated limb. The observed decrease in tremor in 239 the untreated limb, however, is unexpected and its origin is unclear. Anecdotal observations and 240 some reports have suggested that unilateral VIM DBS results in a significant tremor reduction in the arm ipsilateral to the implant<sup>50</sup>, but this ipsilateral benefit of DBS remain controversial and 241 inconclusive.<sup>51–53</sup> It is possible that the tremor improvement observed in the untreated limb of 242 243 our patients may have resulted from a sham/ placebo effect. This interpretation is based on results from recent randomized controlled trial studying the effect of TAPS.<sup>36</sup> Here, Pahwa et. al 244 245 reported that subjects who had received TAPS treatment displayed tremor improvement similar 246 in magnitude to what we see in the treated limb of our subjects (Fig. 2A). Of significance, we 247 see further concordance in the magnitude of tremor improvement between Pahwa et. al's 248 subjects who received sham treatment and the untreated limb of our subjects. Thus, we believe 249 that the improvement in the untreated limb, while statistically significant, is a sham effect. 250 However, we did not test sham-treatments to provide conclusive evidence; future sham-251 controlled studies assessing tremor improvement in both the treated and untreated limb should 252 be performed to demonstrate if unilateral TAPS exerts a bilateral effect on upper limb tremor. 253

Due to the unknown origin of tremor reduction in the untreated limb, we used a fractional difference measure, fTR, to estimate the effect of TAPS in the treated limb over and above the

256 effects common to both limbs. Importantly, tremor improvement scores computed with fTR 257 stratified patients into low and high responders in a similar proportion to previously published methods (i.e. half of the patients were high responders with fTR≥1).<sup>37,38</sup> We found that tremor 258 259 reduction measured by fTR was primarily driven by improvements in kinetic tremor (assessed 260 by spiral drawing, finger-to-nose movement, and dot approximation) rather than postural tremor. 261 This is an interesting result especially considering that kinetic and postural tremors have 262 different characteristic frequencies of oscillation, <6Hz and 6-12Hz, respectively.<sup>3,7-9</sup> It is 263 possible that the alternating burst frequency of TAPS could modified to directly target various 264 tremor subtypes and thereby personalize treatment based on an individual's symptom profile. 265 Consistent with prior studies exploring tremor reduction due to TAPS<sup>36–38</sup>, we found that patients 266 267 experienced varied degrees of tremor improvement. We explored a few possible explanations 268 for the observed heterogeneity in response to TAPS. First, it is possible that engagement of the 269 median and radial nerves at the wrist varied between patients; improper alignment of the 270 stimulation electrode with the underlying anatomy or inadequate stimulation intensity could have 271 diminished therapeutic effects. Here, wristband sizing, positioning, and stimulation parameters 272 for TAPS were determined based on manufacturer's instructions (i.e. tremor frequency 273 measured during postural hold and stimulation amplitude set as the maximum tolerable current 274 for 40 minutes of treatment). Importantly, all subjects verified the presence of paresthesia, not 275 muscle contraction, in the median and radial nerves' hand dermatomes with TAPS activation 276 during both phases of the experiment. The presence of paresthesia referred to the fingertips. 277 lacking reported pain or visible muscle recruitment, indicates engagement of large myelinated 278 proprioceptive and cutaneous afferents (A-alpha and A-Beta fibers) in the median and radial 279 nerve trunks.<sup>54,55</sup> Therefore, subjects likely experienced adequate target nerves engagement. 280 Second, dysfunction in the transmission of sensory information from the peripheral nerve to the 281 central nervous system could contribute to varied efficacy of TAPS. Such dysfunction may be 282 due to the severity of disease or another unknown factor. Importantly, our data showed no 283 relationship between fTR and pre-treatment tremor severity, and no patients in our cohort 284 reported sensory dysfunction. Thus, we expect sensory dysfunction did not impact our results. 285 We did not, however, explicitly characterize proprioceptive or somatosensory acuity in our 286 patients, and are not able to definitively rule out sensory deficits as a factor in the 287 heterogeneous response to TAPS. Thus, relationship between the sensory perception of TAPS 288 and the degree of tremor reduction remains an open question. Full exploration of the effect of 289 the perceived sensation and its relationship to fiber type recruitment will likely require further 290 extra-operative experiments. 291

#### 292 Limitations

293

294 We acknowledge that there are several limitations regarding this work and the conclusions 295 drawn. First, our small cohort size reflects the exploratory nature of this research, as TAPS's 296 effects on CTC network activity had not been previously documented. Future confirmatory 297 studies with pre-registered methodology will be essential to validate and expand on the findings 298 elaborated here. Second, research using intraoperative neural recordings faces inherent 299 limitations due to the clinical priorities of the surgery. For example, the use of sedatives during 300 the DBS procedure may have influenced microelectrode recordings. This concern is likely 301 muted, however, due to the rapid clearance of remifentanil and its minimal effect on neural 302 activity.<sup>56,57</sup> In addition, we also limited surgery duration to minimize infection risks and patient 303 discomfort; thus, we could not test multiple stimulation parameters at each recording depth. 304 Instead, we focused on recording neural activity resulting from TAPS treatment at a single 305 current amplitude and alternating burst frequency. Future work that aims to explore or optimize 306 the effect of stimulation parameters on VIM neural activity should employ chronically implanted

- 307 recording methods. Such methodology would track long-term changes, enabling more robust
- analyses to address the cross-sectional limitations of this study. For example, larger datasets
- 309 from such studies could also support advanced machine learning models to predict and
- 310 optimize TAPS-related tremor reduction on an individual basis. Third, the lab-based
- 311 quantification of TETRAS tremor scores may have induced stress in patients through a "white
- 312 coat effect," potentially biasing our measures of TAPS efficacy compared to home use and
- 313 contributing to the observed response heterogeneity. Though, this is unlikely because the
- heterogeneity in tremor reduction captured by fTR matches the spread in therapeutic effect
- seen by patients with long-terms home use of TAPS.<sup>38</sup> Finally, our results should be applied
- 316 with caution when placed in the context of other non-invasive therapies using peripheral nerve
- 317 stimulation to treat the symptoms of ET as the mechanism of action described here may be
- 318 unique to TAPS.319

#### 320 Conclusion

- 321 TAPS significantly reduced upper limb tremor severity in our cohort of medically refractory ET
- 322 patients, with the treated limb showing greater improvement in kinetic tremor tasks. The
- 323 therapeutic effect was associated with modulation of alpha and beta band local field potentials
- in VIM thalamus, with the greatest modulation proximal to the DBS implant site. In contrast,
- 325 while VIM multiunit spiking activity was also modulated, these changes did not correlate with
- 326 tremor reduction. This dissociation between field potentials and spiking activity suggests TAPS
- 327 may achieve therapeutic benefit by modulating multiple nodes of the CTC network connected to
- 328 VIM, potentially including the motor cortex and cerebellum, rather than through direct effects on
- 329 VIM alone.

#### 330 Material and methods

#### 331

### 332 1.1 Subject Inclusion & Exclusion Criteria333

334 We prospectively enrolled 9 adults with medication refractory ET seeking DBS placement in the 335 VIM. Key inclusion criteria were (1) age between 18 and 85 years old, and (2) a baseline, 336 dominant hand score of 2+ on TETRAS item 6 Archimedes spiral drawing. Spiral drawing score 337 served as one proxy for initial tremor severity, where a score of 2+ was selected to match the severity of subjects recruited in past studies.<sup>36,58</sup> Subjects were excluded if they (1) were 338 339 pregnant or (2) had cognitive disability impairing understanding of the consent process or 340 experimental directions. All subjects provided written informed consent. The study was 341 approved by the Institutional Review Board (IRB) at the University of Wisconsin – Madison (IRB 342 ID: 2018-1052).

343

#### 344 1.2 Transcutaneous Afferent Patterned Stimulation (TAPS)

345

346 We fitted each subject with a wrist-worn stimulator (Cala TWO band, Cala Health, CA, USA) to 347 deliver TAPS on their dominant upper limb. The band hosted pad electrodes targeting the 348 median and radial nerves, in addition to an electrode on the dorsal wrist for electrical return (Fig. 349 1A). After donning the device, the maximum tolerable stimulation current amplitude (mA) and 350 alternating burst frequency (Hz) were calibrated for each subject. To attain the maximum 351 tolerable current, stimulation was increased in 0.25 mA increments until the subject reported 352 paresthesia in both the median and radial nerves' hand dermatomes. The final current was the 353 highest amplitude the subject reported that they could tolerate for 40 minutes. As for the 354 alternating burst frequency, it was measured by on-board accelerometry and determined as the 355 higher of two tremor frequencies after each subject had performed the forward and lateral 356 postural hold tasks. The alternating burst frequency controlled how many alternating stimulation 357 sets are delivered to the median and radial nerves per second (Fig. 1B). Stimulation on each of 358 the median or radial nerve was delivered in biphasic pulses at 150 Hz, each phase lasting 300 359 µs with a 50 µs interphase period.

360

## 361 1.3 Phase 1: Pre-operative Quantification of Tremor Changes Following TAPS362

363 Tremor severity was evaluated using TETRAS, picked for its high sensitivity to tremor changes 364 and reliability between raters.<sup>7</sup> TETRAS contained 9 performance items to rate action tremor in 365 the head, face, voice, limbs and trunk from 0 (no tremor) to 4 (severe tremor) in increments of 366 0.5. Tremor exhibiting a higher amplitude (cm) scored higher in severity. In addition, tremor 367 impact on life quality were also surveyed using the QUEST as these measures hold a modest 368 insight into tremor severity.<sup>59</sup> We scored tremor severity for the dominant and non-dominant 369 limb using TETRAS before and after 40 minutes of TAPS delivered to the wrist of the dominant 370 limb (Fig. 1C). Total upper limb tremor improvement was taken as an average of the differences 371 in scores before and after treatment in 5 tremor tasks described by TETRAS items 4, 6, and 8 372 (Eq. S1). TETRAS item 4 tested (1) forward postural, (2) lateral postural, and (3) kinetic finger-373 to-nose tremors; item 6 tested (4) spiral drawing; and, item 8 tested (5) dot approximation 374 tremor.

374 tre 375

#### 376 1.3.2 Characterizing Tremor Improvement in the Treated Limb

377378 In addition to computing tremor improvement for each limb separately, we were interested

isolating the effect of TAPS in the treated limb from those that were potentially common to both

380 limbs. Here, we used tremor improvement in the untreated limb as a within-subject

normalization factor for the quantification of how TAPS affected tremor in the treated limb.
 Subsequently, the fTR of the treated limb following TAPS was a computed as a fractional

- 383 change in tremor improvement of the treated limb relative to the untreated limb:
- 384
- 385

386

```
fractional Tremor Reduction (fTR) = \frac{Improvement_{treated \ limb \ total} - Improvement_{UNtreated \ limb \ total}}{Improvement_{UNtreated \ limb \ total}} (Eq. 1)
```

- Therefore, fTR estimates the effect of TAPS in the treated limb over and above the effectscommon to both limbs.
- 389
- 390 1.3.3 Comparative Analysis of Clinical Tremor Improvement391

392 Improvement (i.e. the difference between pre- and post-treatment TETRAS score) of the 5 393 individual tremor tasks and the average total score were compared to zero and between limbs 394 using two-sided Wilcoxon signed-rank tests ( $\alpha$ =0.05). To explore the differential impact of TAPS 395 on kinetic and postural tremors and how the improvement of each contributed to overall fTR. 396 measures of kinetic finger-to-nose tremor, spiral drawing tremor, and dot approximation tremor 397 were classified as kinetic tremor while forward postural and lateral postural tremor were grouped 398 as postural tremor.<sup>6</sup> Subsequently, a multilinear regression (Matlab fitlm function) was used to 399 assess the relationship between fTR and the improvement in either kinetic or postural tremors 400 (Supplementary Eq. S2 A,B, α=0.05). An analogous analysis was also done examining the 401 relationship between fTR and TETRAS scores of either tremor type before treatment, a proxy 402 for their initial tremor severity (Supplementary Eq. S2 C,D,  $\alpha$ =0.05).

- 403
- 404 *1.4 Phase 2: Intra-operative Thalamic Recording with Concurrent TAPS Treatment* 405

406 To assess if TAPS causally modulated broadband LFP or spiking activity in the contralateral 407 VIM, we acquired thalamic microelectrode recordings during the mapping phase of each 408 subject's awake DBS surgery (Fig. 2D). Each subject avoided tremor medications for at least 24 409 hours before their operation. Prior to initial sedation, we also fitted a wrist stimulator on their 410 dominant upper limb and verified median and radial hand dermatome paresthesia. Prior to the 411 mapping phase, remiferitanil sedation was discontinued for 15 minutes. During the mapping 412 phase, neural activity from the hemisphere contralateral to the dominant upper limb (i.e. limb 413 fitted with the wrist stimulator) was recorded from an array of 3 microelectrodes, 2 mm apart in 414 the anterior-posterior axis, along a trajectory beginning 10 mm above the target. Here, the 415 electrode in the center of the array was targeted to the VIM using consensus coordinates, 11 mm lateral to the wall of 3rd ventricle at the level of the AC-PC plane, 5.7 mm posterior to the 416 midcommissural point (i.e. x=12, y=-5.7, z=0; Fig. 3C).<sup>60</sup> To map the thalamic nuclei, the 417 418 borders of the ventralis oralis posterior, ventral intermediate, and ventral caudal nuclei were 419 determined based on neural responses evoked by motor, kinesthetic, and somatosensory stimuli on the face and arms.<sup>61</sup> At selected depths along trajectories planned for clinical 420 421 mapping of the relevant nuclei, 60 seconds of microelectrode recordings (MER) was collected 422 for each of two conditions: TAPS treatment ON and treatment OFF. With TAPS treatment ON, 423 subjects were stimulated in for 60 seconds using their calibrated stimulation amplitude and 424 alternating burst frequency from Phase 1. Bipolar neural recordings were made between each 425 microelectrode in the array and separate low impedance macroelectrodes located 1 cm dorsal 426 to the tip of the microelectrode. Signals were bandlimited at 20 kHz and digitized at 48 kHz 427 using the Guideline 4000 LP+ (FHC, Inc, Bodwin, ME). 428

Following the mapping procedure, short bouts of electrical stimulation (biphasic, cathode

430 leading 100 us pulses, 150 Hz, 0-4 mA current amplitude) were delivered through each of the 3

431 macroelectrodes to verify therapeutic efficacy of DBS and assess the resulting side effect 432 profile. The final implant location for the DBS lead was chosen to be region where: 1) test 433 stimulation resulted in the greatest tremor suppression, 2) test stimulation evoked minimal 434 therapy limiting side effects (i.e. paresthesia, muscle contractions and dysarthria), and 3) MER 435 revealed tremor cells and/or neural activity responsive to passive movement of the hand and 436 arm. Putatively this describes the optimal placement of VIM DBS leads for the treatment of ET, 437 projected to be in the ventral VIM 2-4 mm anterior to the border of the ventral caudal nucleus.<sup>61</sup> 438 For purposes of subsequent analyses, the final implant location is considered to be the 439 coordinates that described the placement of the distal edge of the most distal contact on the DBS lead.

#### 440 441

### 441

#### 2 1.4.2 Characterizing Thalamic Local Field Potentials

443

444 Prior to analysis, raw MER were low pass filtered at 7500 Hz and motion artifacts were removed 445 with a custom algorithm that combined Banks et. al's method to ours own (see Supplementary Methods 1.1, Supplementary Fig. S7).<sup>62</sup> We also verified that turning TAPS ON did not induce 446 447 stimulation artifact in thalamic MER (Supplementary Fig. S8) Then, each 60-second MER time 448 series was segmented into 1-second bins and power spectral density (PSD) estimates were 449 computed using Thomson's multi-taper method with Slepian tapers (Matlab pmtm function, time-450 half bandwidth product = 3). Next, area under the curve (AuC) of the PSD, i.e. power, was 451 calculated within canonical LFP frequency bands: delta (1-4 Hz), theta (4-8 Hz), alpha (8-12 Hz), beta (12-30 Hz), low gamma (30-70 Hz), and high gamma (70-200 Hz).<sup>63-66</sup> For each LFP 452 453 frequency band in each 60-second MER time series, power was taken as the median values 454 after calculation was done for all 1-second bins. For each frequency band, we derived the LFP 455 modulation index (MI<sub>LFP</sub>) to characterize how TAPS affect field potentials in the VIM. MI<sub>LFP</sub> was 456 guantified as a fractional change in power (PSD AuC) of the TAPS treatment ON versus OFF 457 conditions (Fig. 3A, B):

459 Modulation Index 
$$(MI)_{LFP \ band} = \frac{Power_{TAPS \ ON, \ banded - Power_{TAPS \ OFF, \ banded}}{Power_{TAPS \ OFF, \ banded}}$$
 (Eq. 2)

460

461 1.4.3 Characterizing Thalamic Neural Spiking Activities

462

463 We also examined the effect of TAPS on spiking activity (see Supplementary Methods 1.2). 464 Briefly, spike detection was performed by marking times where the preprocessed MER time 465 series rises above 5 standard deviations from the series' mean signal (Fig. 4A). Recordings with 466 likely multiunit activity were further filtered for if their spike rate was at least 1 Hz during the 467 treatment OFF condition. Next, spike times for each time series were binned (1 second bin 468 width) and a custom bootstrap resampling procedure was used to estimate the distribution of 469 spike rates (Fig. 4B). The firing rate of each example of multiunit activity was estimated as the 470 median of the bootstrapped distribution. Bootstrap resampling was done to reduce bias from 471 unequal time series duration after artifact removal. Similar to MILFP, we calculated the 472 modulation index for spiking activity (MI<sub>Spikes</sub>) to quantify fractional changes during the TAPS 473 treatment ON versus OFF conditions (Fig. 4E, F): 474

475 Modulation Index 
$$(MI)_{Spikes} = \frac{Spikes_{TAPS ON} - Spikes_{TAPS OFF}}{Spikes_{TAPS OFF}}$$
 (Eq. 3)  
476

477 1.4.4 Comparative Analysis

478

479 Linear regression models were used to examine the relationship between either MI<sub>LFP</sub> or MI<sub>Spikes</sub>
 480 and either the distance from the implant location (DIL, mm) (see Supplementary Methods 1.3) or

- 481 fractional tremor reduction (fTR) (Supplementary Eq. S3, S4). Histologically, the VIM measures
- about 4 mm anterioposteriorly, 4 mm mediolaterally, and 6 mm dorsoventrally.<sup>67–69</sup> Thus, we
- 483 approximated the diameter of the VIM to be 5 mm and segregated MER data at this threshold.
- 484 An  $\alpha$ =0.05 error rate was used for MI<sub>Spikes</sub> comparisons. For MI<sub>LFP</sub> comparisons, we further
- 485 applied a Bonferroni multi-comparison correction such that  $\alpha$ '=0.008 was used as the most
- 486 appropriate threshold of significance since regression for MI<sub>LFP</sub> involved 6 bands. All analyses
   487 and statistical comparisons were performed in MATLAB 2024a (Mathworks, Natick, MA).
- 487 and statistical compansons were performed in MATLAB 2024a (Mathworks, Natick, MA). 488

#### 489 Data availability

- 490
- 491 Raw neural data structures are not openly available due to the inclusion of private health
- information and are available from the corresponding author upon reasonable request. The de-
- identified data supporting the findings of this study will be shared on DRYAD once accepted for
- 494 publication.

#### 495 **References**

- 496 1.Song, P. *et al.* The global prevalence of essential tremor, with emphasis on age and sex: A
  497 meta-analysis. *J. Glob. Health* **11**, 04028.
- 498 2. Thanvi, B., Lo, N. & Robinson, T. Essential tremor—the most common movement
  499 disorder in older people. *Age Ageing* **35**, 344–349 (2006).
- 3. Bhatia, K. P. *et al.* Consensus Statement on the classification of tremors. from the task
   force on tremor of the International Parkinson and Movement Disorder Society. *Mov. Disord.* 33, 75–87 (2018).
- 4. Louis, E. D. *et al.* Correlates of functional disability in essential tremor. *Mov. Disord.* 16,
  914–920 (2001).
- 505 5. Biary, N. & Koller, W. Kinetic predominant essential tremor: Successful treatment with 506 clonazepam. *Neurology* **37**, 471–471 (1987).
- 6. Charles, P. D., Esper, G. J., Davis, T. L., Maciunas, R. J. & Robertson, D. Classification of
  Tremor and Update on Treatment. *Am. Fam. Physician* 59, 1565–1572 (1999).
- 509 7. Elble, R. *et al.* Task force report: Scales for screening and evaluating tremor: Critique and
   510 recommendations. *Mov. Disord.* 28, 1793–1800 (2013).
- 8. Agarwal, S. & Biagioni, M. C. Essential Tremor. in *StatPearls* (StatPearls Publishing,
  Treasure Island (FL), 2024).
- 9. Calzetti, S., Baratti, M., Gresty, M. & Findley, L. Frequency/amplitude characteristics of
  postural tremor of the hands in a population of patients with bilateral essential tremor:
  implications for the classification and mechanism of essential tremor. *J. Neurol. Neurosurg. Psychiatry* **50**, 561–567 (1987).
- 517 10. Louis, E. D. *et al.* Heterotopic Purkinje Cells: a Comparative Postmortem Study of
  518 Essential Tremor and Spinocerebellar Ataxias 1, 2, 3, and 6. *The Cerebellum* **17**, 104–
  519 110 (2018).
- 520 11. Shill, H. A. *et al.* Pathologic findings in prospectively ascertained essential tremor
   521 subjects. *Neurology* **70**, 1452–1455 (2008).
- 522 12. DeSimone, J. C., Archer, D. B., Vaillancourt, D. E. & Wagle Shukla, A. Network-level
   523 connectivity is a critical feature distinguishing dystonic tremor and essential tremor.
   524 Brain 142, 1644–1659 (2019).
- 525 13. Roy, A. *et al.* Cortical dynamics within and between parietal and motor cortex in
  526 essential tremor. *Mov. Disord.* 34, 95–104 (2019).
- 527 14. Dum, R. P. & Strick, P. L. An Unfolded Map of the Cerebellar Dentate Nucleus and its
   528 Projections to the Cerebral Cortex. J. Neurophysiol. 89, 634–639 (2003).
- 529 15. Mai, J. K. & Majtanik, M. Toward a Common Terminology for the Thalamus. *Front.*530 *Neuroanat.* 12, (2019).
- 531 16. Evarts, E. V. & Tanji, J. Reflex and intended responses in motor cortex pyramidal tract
   532 neurons of monkey. J. Neurophysiol. 39, 1069–1080 (1976).
- 533 17. Thach, W. T. Correlation of neural discharge with pattern and force of muscular activity,
  534 joint position, and direction of intended next movement in motor cortex and
  535 cerebellum. J. Neurophysiol. 41, 654–676 (1978).
- 536 18. Strick, P. L. Cerebellar involvement in volitional muscle responses to load changes. in
   537 Cerebral Motor Control in Man: Long Loop Mechanisms vol. 4 (Karger, Basel, 1978).

- 538 19. Suminski, A. J., Rao, S. M., Mosier, K. M. & Scheidt, R. A. Neural and electromyographic 539 correlates of wrist posture control. *J. Neurophysiol.* **97**, 1527–1545 (2007).
- Suminski, A. J., Doudlah, R. C. & Scheidt, R. A. Neural Correlates of Multisensory
   Integration for Feedback Stabilization of the Wrist. *Front. Integr. Neurosci.* 16, (2022).
- 542 21. Haubenberger, D. & Hallett, M. Essential Tremor. N. Engl. J. Med. 378, 1802–1810
  543 (2018).
- 544 22. Louis, E. D., Rios, E. & Henchcliffe, C. How are we doing with the treatment of essential
  545 tremor (ET)? *Eur. J. Neurol.* 17, 882–884 (2010).
- 546 23. Soto, M. C. S. Essential tremor: New advances. (2020).
- 547 24. Dallapiazza, R. F. *et al.* Outcomes from stereotactic surgery for essential tremor. *J.* 548 *Neurol. Neurosurg. Psychiatry* **90**, 474–482 (2019).
- 549 25. Kim, M.-R. *et al.* Patients' reluctance to undergo deep brain stimulation for Parkinson's
  550 disease. *Parkinsonism Relat. Disord.* 23, 91–94 (2016).
- 26. Elias, W. J. *et al.* A Pilot Study of Focused Ultrasound Thalamotomy for Essential
  Tremor. *N. Engl. J. Med.* **369**, 640–648 (2013).
- 553 27. Elias, W. J. *et al.* A Randomized Trial of Focused Ultrasound Thalamotomy for Essential
   554 Tremor. *N. Engl. J. Med.* **375**, 730–739 (2016).
- 28. Cosgrove, G. R. *et al.* Magnetic resonance imaging–guided focused ultrasound
  thalamotomy for essential tremor: 5-year follow-up results. *J. Neurosurg.* 138, 1028–
  1033 (2022).
- 29. Park, Y.-S., Jung, N. Y., Na, Y. C. & Chang, J. W. Four-year follow-up results of magnetic
  resonance-guided focused ultrasound thalamotomy for essential tremor. *Mov. Disord.*34, 727–734 (2019).
- 30. Bruno, F. *et al.* MRgFUS thalamotomy for the treatment of tremor: evaluation of learning
   curve and operator's experience impact on the procedural and clinical outcome. *Acta Neurochir. (Wien)* 165, 727–733 (2023).
- 564 31. FDA. DEN170028. Device Classification Under Section 513(f)(2)(De Novo)
  565 https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/denovo.cfm?ID=DEN1700
  566 28.
- 567 32. Fukushima, T., Mayanagi, Y. & Bouchard, G. Thalamic evoked potentials to
  568 somatosensory stimulation in man. *Electroencephalogr. Clin. Neurophysiol.* 40, 481–
  569 490 (1976).
- 33. Hernandez-Martin, E., Arguelles, E., Deshpande, R. & Sanger, T. D. Evoked Potentials
  During Peripheral Stimulation Confirm Electrode Location in Thalamic Subnuclei in
  Children With Secondary Dystonia. J. Child Neurol. 35, 799–807 (2020).
- 573 34. Tsuji, S., Shibasaki, H., Kato, M., Kuroiwa, Y. & Shima, F. Subcortical, thalamic and
   574 cortical somatosensory evoked potentials to median nerve stimulation.
- 575 Electroencephalogr. Clin. Neurophysiol. Potentials Sect. **59**, 465–476 (1984).
- 576 35. Popovych, O. V. & Tass, P. A. Control of Abnormal Synchronization in Neurological
  577 Disorders. *Front. Neurol.* 5, 268 (2014).
- 36. Pahwa, R. *et al.* An Acute Randomized Controlled Trial of Noninvasive Peripheral Nerve
  Stimulation in Essential Tremor. *Neuromodulation Technol. Neural Interface* 22, 537–
  545 (2019).

- 581 37. Isaacson, S. H. *et al.* Prospective Home-use Study on Non-invasive Neuromodulation
   582 Therapy for Essential Tremor. *Tremor Hyperkinetic Mov. N. Y. N* 10, 29 (2020).
- 38. Lu, C., Khosla, D., Kent, A., Bronte-Stewart, H. M. & Rosenbluth, K. H. Transcutaneous
  Afferent Patterned Stimulation for Essential Tremor: Real-World Evidence with Long
  Term Follow-Up. *Tremor Hyperkinetic Mov.* 13, 29 (2023).
- 586 39. Pascual-Valdunciel, A. Non-invasive electrical stimulation of peripheral nerves for the
   587 management of tremor. J. Neurol. Sci. (2022).
- 40. Wagle Shukla, A. Rationale and Evidence for Peripheral Nerve Stimulation for Treating
   Essential Tremor. *Tremor Hyperkinetic Mov.* 12, 20.
- 41. Barath, A. S. *et al.* Brain Metabolic Changes with Longitudinal Transcutaneous Afferent
  Patterned Stimulation in Essential Tremor Subjects. *Tremor Hyperkinetic Mov. N. Y. N*10, 52 (2020).
- 42. Gironell, A., Ribosa-Nogué, R., Gich, I., Marin-Lahoz, J. & Pascual-Sedano, B. Severity
  Stages in Essential Tremor: A Long-Term Retrospective Study Using the Glass Scale. *Tremor Hyperkinetic Mov.* 5, 299 (2015).
- 43. Louis, E. D. & Faust, P. L. Essential tremor: the most common form of cerebellar
  degeneration? *Cerebellum Ataxias* 7, 1–10 (2020).
- 44. Molnar, G. F., Pilliar, A., Lozano, A. M. & Dostrovsky, J. O. Differences in Neuronal Firing
  Rates in Pallidal and Cerebellar Receiving Areas of Thalamus in Patients With
  Parkinson's Disease, Essential Tremor, and Pain. J. Neurophysiol. 93, 3094–3101 (2005).
- 45. Pedrosa, D. J. *et al.* Essential tremor and tremor in Parkinson's disease are associated
  with distinct 'tremor clusters' in the ventral thalamus. *Exp. Neurol.* 237, 435–443
  (2012).
- 46. Kane, A., Hutchison, W. D., Hodaie, M., Lozano, A. M. & Dostrovsky, J. O. Enhanced
  synchronization of thalamic theta band local field potentials in patients with essential
  tremor. *Exp. Neurol.* 217, 171–176 (2009).
- 47. Filip, P., Lungu, O. V., Manto, M.-U. & Bareš, M. Linking Essential Tremor to the
  Cerebellum: Physiological Evidence. *The Cerebellum* 15, 774–780 (2016).
- 48. Hua, S. E. & Lenz, F. A. Posture-Related Oscillations in Human Cerebellar Thalamus in
  Essential Tremor Are Enabled by Voluntary Motor Circuits. *J. Neurophysiol.* 93, 117–127
  (2005).
- 49. Pesaran, B. Neural correlations, decisions, and actions. *Curr. Opin. Neurobiol.* 20, 166–
  171 (2010).
- 50. Peng-Chen, Z. *et al.* Unilateral thalamic deep brain stimulation in essential tremor
  demonstrates long-term ipsilateral effects. *Parkinsonism Relat. Disord.* 19, 1113–1117
  (2013).
- 617 51. Lin, Z., Zhang, C., Li, D. & Sun, B. Lateralized effects of deep brain stimulation in 618 Parkinson's disease: evidence and controversies. *Npj Park. Dis.* **7**, 1–8 (2021).
- 52. Österlund, E., Blomstedt, P. & Fytagoridis, A. Ipsilateral Effects of Unilateral Deep Brain
  Stimulation for Essential Tremor. *Stereotact. Funct. Neurosurg.* 100, 248–252 (2022).
- 53. Kim, M. J., Jeon, S. R., Kim, S. R., Lee, M. C. & Chung, S. J. Lateralized Effects of
- 622 Unilateral Thalamotomy and Thalamic Stimulation in Patients with Essential Tremor. J.
  623 Mov. Disord. 4, 64 (2011).

624 54. Nicolai, E. N. et al. Sources of off-target effects of vagus nerve stimulation using the 625 helical clinical lead in domestic pigs. J. Neural Eng. 17, 046017 (2020). 626 55. Chang, Y.-C. et al. Quantitative estimation of nerve fiber engagement by vagus nerve 627 stimulation using physiological markers. Brain Stimulat. 13, 1617–1630 (2020). 628 56. Michelsen, L. G. & Hug, C. C. The pharmacokinetics of remifentanil. J. Clin. Anesth. 8, 629 679-682 (1996). 630 57. Bos, M. J. et al. Effect of Anesthesia on Microelectrode Recordings During Deep Brain 631 Stimulation Surgery: A Narrative Review. J. Neurosurg. Anesthesiol. 33, 300 (2021). 632 58. Lin, P. T. et al. Noninvasive neuromodulation in essential tremor demonstrates relief in a 633 sham-controlled pilot trial. Mov. Disord. 33, 1182–1183 (2018). 634 59. Tröster, A. I., Pahwa, R., Fields, J. A., Tanner, C. M. & Lyons, K. E. Quality of life in 635 Essential Tremor Questionnaire (QUEST): Development and initial validation. 636 Parkinsonism Relat. Disord. 11, 367–373 (2005). 637 60. Wakim, A. A. et al. Direct targeting of the ventral intermediate nucleus of the thalamus 638 in deep brain stimulation for essential tremor: a prospective study with comparison to a 639 historical cohort. J. Neurosurg. 136, 662-671 (2022). 640 61. Gross, R. E., Krack, P., Rodriguez-Oroz, M. C., Rezai, A. R. & Benabid, A.-L. 641 Electrophysiological mapping for the implantation of deep brain stimulators for 642 Parkinson's disease and tremor. Mov. Disord. 21, S259–S283 (2006). 643 62. Banks, M. I. et al. Functional geometry of auditory cortical resting state networks 644 derived from intracranial electrophysiology. PLOS Biol. 21, e3002239 (2023). 645 63. Thompson, J. A., Lanctin, D., Ince, N. F. & Abosch, A. Clinical Implications of Local Field 646 Potentials for Understanding and Treating Movement Disorders. Stereotact. Funct. 647 Neurosurg. 92, 251–263 (2014). 648 64. Ray, S., Crone, N. E., Niebur, E., Franaszczuk, P. J. & Hsiao, S. S. Neural Correlates of 649 High-Gamma Oscillations (60–200 Hz) in Macaque Local Field Potentials and Their 650 Potential Implications in Electrocorticography. J. Neurosci. 28, 11526–11536 (2008). 651 65. Womelsdorf, T. et al. Modulation of Neuronal Interactions Through Neuronal 652 Synchronization. Science 316, 1609–1612 (2007). 653 66. Schoffelen, J.-M., Oostenveld, R. & Fries, P. Neuronal Coherence as a Mechanism of 654 Effective Corticospinal Interaction. Science 308, 111–113 (2005). 655 67. Hirai, T., Ohye, C., Nagaseki, Y. & Matsumura, M. Cytometric analysis of the thalamic 656 ventralis intermedius nucleus in humans. J. Neurophysiol. 61, 478-487 (1989). 657 68. Morel, A., Magnin, M. & Jeanmonod, D. Multiarchitectonic and stereotactic atlas of the 658 human thalamus. J. Comp. Neurol. 387, 588-630 (1997). 659 69. Najdenovska, E. et al. Comparison of MRI-based automated segmentation methods 660 and functional neurosurgery targeting with direct visualization of the Ventro-661 intermediate thalamic nucleus at 7T. Sci. Rep. 9, 1119 (2019). 662


#### 663 **Table**

Table 1. Demographic, Baseline Severity, and TAPS Settings

Table 1. Demographic, Dasem		inty, an		o ocum	iga					
Subject	1	2	3	4	5	6	7	8	9	Cohort Summary
Age (decade)	50s	70s	70s	60s	50s	70s	60s	60s	60s	65 ± 7
Sex	М	М	F	М	М	М	М	F	М	Male: 78%
Age of Onset (decade)	10s	10s	60s	30s	20s	10s	20s	40s	50s	29 ± 17
Family History	1	1	0	1	1	1	0	0	0	56%
Specific Current Co-Therapy										
Propranolol	1	1	1	0	0	1	0	1	1	67%
Primidone	1	1	1	0	0	0	0	0	0	33%
Gabapentin	0	1	1	0	0	0	0	0	0	22%
Initial QUEST Life Disability Scores (Frequency Range: 0-100%)										
Tremor During Waking Hours	89	83	56	89	89	89	94	94	56	82.1 ± 15.4
Communication	17	0	0	67	0	42	25	0	25	19.5 ± 23.2
Work and Finance	50	0	38	8	42	67	33	0	8	27.3 ± 24
Hobbies and Leisure	83	92	100	100	75	100	58	92	67	85.2 ± 15.5
Physical	64	28	100	64	31	97	75	78	58	66.1 ± 25.2
Psychosocial	61	17	58	33	39	31	64	28	8	37.7 ± 19.8
Initial TETRAS Scores (Averaged Across Tasks, Severity Range: 0-4)										
Archimedes Spiral (Task 6)	3.0	3.0	4.0	2.0	2.0	2.0	3.0	4.0	2.0	2.8 ± 0.8
Upper Limb Tremor (Tasks 4, 6, 8)	2.0	2.4	3.1	1.7	2.0	2.1	2.7	3.0	1.8	2.3 ± 0.5
Total Task Score (Tasks 1-9)	1.7	1.5	2.2	1.5	1.5	1.3	1.7	2.2	1.0	1.6 ± 0.4
TAPS Settings										
Dominant Hand	Right	Left	Right	Left	Right	Right	Right	Right	Right	Right: 78%
Tremor Frequency (Hz)	5.4	4.5	4.5	4.5	5.7	8.1	5.3	6.5	4.1	5.4 ± 1.3
Stimulation Current (mA)	7.0	7.0	6.5	7.3	5.8	6.5	7.8	6.0	9.5	7.0 ± 1.1

Range displayed as mean ± 1 standard deviation.

664




670 A Demonstration of the wrist stimulation band placement on the dominant hand, showing the 3 671 electrodes used for the TAPS paradigm. Stimulator unlatched from the dorsal wrist, seen more

672 clearly in (C). B TAPS delivers alternating pulse trains to the median and radial nerves at a

673 burst frequency matched to each patient's tremor frequency. Stimulation amplitude is set to the

- 674 maximum tolerable level reported by each patient. C During phase 1 (pre-operative), tremor
- 675 severity is assessed using TETRAS scores before and after a 40-minute TAPS session. D
- 676 During phase 2 (intra-operative), MER are collected along the planned DBS trajectory targeting
- the VIM nucleus of the thalamus, with TAPS alternating between the ON and OFF states. 677

<sup>668</sup> Figure 1. Investigating the effect of TAPS on clinical tremor scores and thalamus neural 669 activity in essential tremor patients.



678 (kinetic tremor + spiral drawing + dot approximation)<sub>Residuals</sub> (forward postural + lateral postural)<sub>Residuals</sub>
 679 Figure 2. TAPS treatment improves essential tremor symptoms, with enhanced impact on
 680 kinetic tremor relative to postural tremor in the treated limb (n=8).

681 A Mean ± SEM improvement in average upper limb tremor scores after 40 minutes of TAPS

treatment, comparing the treated versus untreated limb across all patients (\*two-sided signed-

rank p=0.029). **B–C** Representative examples showing changes in spiral consistency and


amplitude following TAPS treatment in patients with **(B)** low fTR (cyan) and **(C)** high fTR

685 (orange). **D–E** Multiple linear regression analyses showing the relationship between fTR and


aggregated improvement in (D) kinetic tremor tasks and (E) postural tremor tasks. To visualize

the regression model, the x-axis rescales the combined effect of all independent variables,

adjusted using the Frisch–Waugh–Lovell theorem (Matlab fitlm).




- 689
- 690



693 **A–B** Representative power spectral density (PSD) estimates comparing (A) low  $\alpha$ -band 694 modulation index ( $MI_{I FP-\alpha}$ ) in a patient with low fTR (cyan) versus (**B**) high  $MI_{I FP-\alpha}$  in a patient 695 with high fTR (orange). Black and gray lines show Treatment ON and OFF conditions, 696 respectively. C Schematic illustrating MER distance relative to the final implant location within 697 the thalamus (defined as the distal edge of the DBS lead's distal contact). MER locations are 698 classified as within VIM (red) or outside VIM (blue). **D–E** Correlation between  $MI_{LFP-q}$  and 699 distance from implant location (DIL) for recordings within VIM (red) and outside VIM (blue) (n=8). Points indicate MER data from individual depths, superimposed by best-fit lines and 95% 700 701 confidence intervals. F Mean regression slope coefficients ± 2 SEM showing the relationship 702 between MI<sub>LFP-Band</sub> and DIL for recordings within VIM (red) and outside VIM (blue). § indicates 703 regression slope coefficient with  $p \le 0.008$  (Bonferroni-corrected  $\alpha$ ' threshold). (See 704 supplementary Fig. S5 for expanded regression plots.) **G–H** Correlation between  $MI_{LFP-q}$  and 705 fTR for recordings within VIM (red) and outside VIM (blue). I Mean regression slope coefficients 706  $\pm 2$  SEM showing the relationship between MI<sub>LFP-Band</sub> and fTR for recordings within VIM (red) 707 and outside VIM (blue). § indicates regression slope coefficient with p≤0.008 (Bonferroni-

708 corrected α' threshold). (See supplementary Fig. S6 for expanded regression plots.)



709 710

Figure 4. Modulation of spiking activity in thalamic MER under TAPS treatment ON and

#### 711 **OFF** conditions.

712 A-B Sample time series of multiunit activity recorded 0.5 mm from the final implant location

713 within the VIM thalamus during TAPS treatment (A) OFF and (B) ON periods. Spike rates (Hz)

714 were calculated in consecutive, non-overlapping 1-second segments of the recordings, then

715 aggregated for bootstrap resampling. **C–D** Spike rate distributions obtained through 10,000

716 bootstrap resampling iterations of the rates collected from recordings shown in (A) and (B),

717 during TAPS (C) OFF and (D) ON conditions, respectively. Vertical lines indicate median spike

rates, representing the most likely spike rate for each recording. E-F Simple linear correlations 718

719 between MI<sub>Spikes</sub> and (E) DIL or (F) fTR. Data points represent individual recordings taken ≤5mm

720 from the implant location (red) with baseline spike rates >1Hz during TAPS OFF. Best-fit lines

721 with 95% confidence intervals are shown.